- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00174655
BIG 02/98 Docetaxel - Breast Cancer
An Intergroup Phase III Trial to Evaluate the Activity of Docetaxel, Given Either Sequentially or in Combination With Doxorubicin, Followed by CMF, in Comparison to Doxorubicin Alone or in Combination With Cyclophosphamide, Followed by CMF, in the Adjuvant Treatment of Node-positive Breast Cancer Patients.
Primary objectives:
- To compare Disease-Free Survival (DFS) of an adjuvant treatment with docetaxel given either sequentially or in combination with doxorubicin and followed by CMF to doxorubicin alone or in combination with cyclophosphamide and followed by CMF in operable breast cancer patients with positive axillary lymph nodes.
Secondary objectives:
- To compare DFS of an adjuvant treatment with doxorubicin followed by docetaxel followed by CMF to doxorubicin followed by CMF in operable breast cancer patients with positive axillary lymph nodes
- To compare DFS of an adjuvant treatment with docetaxel in combination with doxorubicin followed by CMF to doxorubicin in combination with cyclophosphamide followed by CMF in operable breast cancer patients with positive axillary lymph nodes
- To compare DFS of an adjuvant treatment with doxorubicin followed by docetaxel followed by CMF to doxorubicin in combination with docetaxel followed by CMF in operable breast cancer patients with positive axillary lymph nodes, (sequential mono-chemotherapy versus polychemotherapy).
- To compare overall survival of treatment arms.
- To compare toxicity of treatment arms.
- To evaluate pathologic and molecular markers for predicting efficacy.
- Socioeconomic data will be collected in order to be able to perform a socioeconomic analysis by country, when needed.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Macquarie Park, Australia
- Sanofi-Aventis
-
-
-
-
-
Vienna, Austria
- Sanofi-Aventis
-
-
-
-
-
Diegem, Belgium
- Sanofi-Aventis
-
-
-
-
-
Sao Paulo, Brazil, ao
- Sanofi-Aventis
-
-
-
-
-
Providencia Santiago, Chile
- Sanofi-Aventis
-
-
-
-
-
Praha, Czech Republic
- Sanofi-Aventis
-
-
-
-
-
Horsholm, Denmark
- Sanofi-Aventis
-
-
-
-
-
Berlin, Germany
- Sanofi-Aventis
-
-
-
-
-
Budapest, Hungary
- Sanofi-Aventis
-
-
-
-
-
Dublin, Ireland
- Sanofi-Aventis
-
-
-
-
-
Natanya, Israel
- Sanofi-Aventis
-
-
-
-
-
Milan, Italy
- Sanofi-Aventis
-
-
-
-
-
Auckland, New Zealand
- Sanofi-Aventis
-
-
-
-
-
Porto Salvo, Portugal
- Sanofi-Aventis
-
-
-
-
-
Bratislava, Slovakia
- Sanofi-Aventis
-
-
-
-
-
Ljubljana, Slovenia
- Sanofi-Aventis
-
-
-
-
-
Gauteng, South Africa
- Sanofi-Aventis
-
-
-
-
-
Barcelona, Spain
- Sanofi-Aventis
-
-
-
-
-
Bromma, Sweden
- Sanofi-Aventis
-
-
-
-
-
Geneve, Switzerland
- Sanofi-Aventis
-
-
-
-
-
Guildford Surrey, United Kingdom
- Sanofi-Aventis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically proven breast cancer. Interval between definitive surgery that includes axillary lymph node dissection and registration must be less than 60 days. A representative sample of the primary tumor (either blocks or slides) must be sent to the operational office, for central pathology reviews, after patients randomization.
- Definitive surgical treatment must be either mastectomy or breast conserving surgery, with axillary lymph node dissection (not sampling) for operable breast cancer (clinical T1-3, N0-1, M0). Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in situ (DCIS). Lobular carcinoma in-situ does not count as a positive margin. Patients with histologically-documented infiltration of the skin (pT4) will not be eligible. Patients who have a breast conserving procedure with a positive margin may become eligible if they subsequently undergo adequate resection or mastectomy with clear margins.
- Histologic examination of the tumor: invasive adenocarcinoma with at least one axillary lymph node (pN1) showing evidence of tumor among a minimum of eight resected lymph nodes. All nodes must be examined by the pathologist. The determination of ER (estrogen receptor) and PgR (progesterone receptor) is mandatory and results must be known by the end of chemotherapy in order to decide whether hormonal therapy is indicated (Biochemical or immunohistochemical methods required ; ER and/or PgR positivity should be in accordance with the policy in use at each participating center. Each center will specify its own policy).
- Age > or = 18 years and age < or = 70 years. The upper age limit is not meant to be exclusionary but rather is based on the lack of safety data for women > 70 years of age.
- Karnofsky Performance status index > or = 70 %.
- Normal cardiac function must be confirmed by LVEF (MUGA scan or echocardiography). The result must be above the lower limit of normal for the institution.
Laboratory requirements: (within 14 days prior to registration)
Hematology
- Neutrophils > or = 2.0 x 109/L
- Platelets > or =100 x 109/L
- Hemoglobin > or = 10 g/dL
Hepatic function
- Total bilirubin < or = 1 UNL
- ASAT (SGOT) and ALAT (SGPT) < or = 1.5 UNL
- Alkaline phosphatase < or = 2.5 UNL
Renal function
- Creatinine < or = 150 µmol/L (1.5 mg/dL)
- If creatinine is borderline, the calculated creatinine clearance should be > or = 60 mL/min (Cockcroft formula).
- Complete staging work-up within 3 months prior to registration. All patients will have bilateral mammography, chest X-ray (PA and lateral) and/or CT-scan, abdominal ultrasound and/or CT scan, bone scan (in case of positive bone scan suspicious for metastases, bone X-ray (or bone CT-scan for spine) on hot spots is mandatory to rule out the possibility of metastatic hot spots). Other tests may be performed as clinically indicated.
- Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at a participating center which could be a Principal or a co-investigator's site. In case patient moves during the follow-up, every effort should be done to follow the patient in a participating center.
- Negative pregnancy test (urine or serum) within 7 days prior to registration for all women of childbearing potential. Patients of childbearing potential must implement adequate non-hormonal measures to avoid pregnancy during study treatment(chemotherapy, radiotherapy and hormonal therapy).
Exclusion Criteria:
- Prior systemic anticancer therapy for breast cancer (chemo-immuno-hormonotherapy).
- Prior radiation therapy for breast cancer.
- Pregnant, or lactating patients.
- Any locally advanced (clinical or pathological T4 and/or N2-known N3) or metastatic(M1) breast cancer.Patients with inoperable residual axillary nodal disease or with supraclavicular nodes.
- Pre-existing motor or sensory neurotoxicity of a severity ³ grade 2 by NCI criteria.
Other serious illness or medical condition:
- congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias
- history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent
- active uncontrolled infection
- active peptic ulcer, unstable diabetes mellitus
Past or current history of other neoplasms except for:
- curatively treated basal cell skin cancer
- adequately treated in situ carcinoma of the cervix
In regard to past or current history of other breast carcinoma, criteria of exclusion are:
- past history of ipsilateral or past or current history of contralateral invasive breast carcinoma
- past or current history of contralateral ductal in situ breast carcinoma
A past or current history of ipsilateral ductal in situ or lobular in situ (ipsilateral or contralateral) breast carcinoma is not a criterion of exclusion.
- Chronic treatment with corticosteroids unless initiated > 6 months prior to study entry and at low dose (< or = 20 mg methylprednisolone or equivalent).
- Concurrent treatment with hormonal replacement therapy. Prior treatment should be stopped before study entry.
- Definite contraindications for the use of corticosteroids.
- Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.
- Concurrent treatment with any other anti-cancer therapy.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: B
|
doxorubicin 75 mg/m² i.v.
day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
|
EXPERIMENTAL: C
|
doxorubicin 50 mg/m² i.v.
+ docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
|
ACTIVE_COMPARATOR: A1
|
doxorubicin 75 mg/m² i.v.
day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v.
days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v.
days 1 and 8, q 28 days for 3 cycles
|
ACTIVE_COMPARATOR: A2
|
doxorubicin 60 mg/m² i.v.
+ cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
DFS of docetaxel arms versus non toxanes arm (DFS: interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer or death for any cause whichever occurs first.
Time Frame: 810 events or median 5 year follow-up whichever occurs first
|
810 events or median 5 year follow-up whichever occurs first
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
DFS sequential/combined arms
Time Frame: 810 events or median 5 year follow-up whichever occurs first
|
810 events or median 5 year follow-up whichever occurs first
|
Safety NCI common toxicity criteria
Time Frame: from baseline to study end
|
from baseline to study end
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA, Sotiriou C, Piccart M, Biganzoli E. Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index. J Clin Oncol. 2020 Sep 1;38(25):2883-2891. doi: 10.1200/JCO.19.01771. Epub 2020 Jul 2.
- Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell'orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Leo AD, Olivier M. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res. 2012 May 2;14(3):R70. doi: 10.1186/bcr3179.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Docetaxel
- Cyclophosphamide
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- RP56976_PR_315
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCActive, not recruitingBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
BerGenBio ASAMerck Sharp & Dohme LLCTerminatedTriple Negative Breast Cancer | Inflammatory Breast Cancer Stage IVSpain, United States, United Kingdom, Norway
-
CytomX TherapeuticsCompletedNeoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 NegativeUnited States, Spain, Korea, Republic of
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Dana-Farber Cancer InstituteConquer Cancer FoundationRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Inflammatory Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of BreastUnited States
Clinical Trials on doxorubicine + cyclophosphamide sequential
-
RezoluteCompletedCongenital HyperinsulinismUnited States, Denmark, United Kingdom, Russian Federation, Spain, Bulgaria, Canada, Georgia, Germany, Israel, Turkey
-
Swanson CenterCompletedBlood Coagulation DisorderUnited States
-
French Innovative Leukemia OrganisationCompleted
-
Chang Gung Memorial HospitalEnrolling by invitationMild Cognitive ImpairmentTaiwan
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedGastritis | Helicobacter Pylori Infection | Gastric Ulcer | Duodenal Ulcer | Non Ulcer Dyspepsia | Chronic Active GastritisItaly
-
University of TartuNot yet recruitingAcute Mesenteric Ischemia
-
University of CalgaryRecruitingOrthostatic Hypotension | Neurogenic Orthostatic HypotensionCanada
-
Abramson Cancer Center at Penn MedicineEnrolling by invitationOvarian Cancer | Genetic Predisposition to Disease | Breast Cancer Female | Hereditary Diseases | Gene Mutation-Related Cancer | Hereditary Breast and Ovarian Cancer | Hereditary Cancer SyndromeUnited States
-
Rigshospitalet, DenmarkRecruiting
-
Rigshospitalet, DenmarkNot yet recruitingCharles Bonnet Syndrome | Bilateral CataractDenmark